This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Estrogen Treatment in Acromegalic Women

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2006 by Université de Montréal.
Recruitment status was:  Recruiting
Information provided by:
Université de Montréal Identifier:
First received: April 13, 2006
Last updated: May 25, 2006
Last verified: May 2006
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

Condition Intervention Phase
Acromegaly Drug: Alesse Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by NLM:

Further study details as provided by Université de Montréal:

Estimated Enrollment: 30
Study Start Date: May 2006
Estimated Study Completion Date: August 2007
Detailed Description:
This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women 18 years and older treated with somatostatin analogs
  • Active acromegaly

Exclusion Criteria:

  • Cardiovascular or cerebrovascular disease
  • Thrombophlebitis or thromboembolism
  • Breast cancer
  • Non-controlled arterial hypertension
  • Smoking
  • Pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00315107

Contact: Omar SERRI, MD 514-890-8000 ext 25607

Canada, Quebec
CHUM - Notre-Dame Hospital Recruiting
Montreal, Quebec, Canada, H2L 4M1
Principal Investigator: Omar Serri, MD         
Sponsors and Collaborators
Université de Montréal
Principal Investigator: Omar Serri, MD CHUM- Endocrinology
  More Information Identifier: NCT00315107     History of Changes
Other Study ID Numbers: HND01
Study First Received: April 13, 2006
Last Updated: May 25, 2006

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 19, 2017